In contrast to the high cure rates in the dimeticone group, cure rates in the permethrin group were 67%and68%8% at days 2 and 9. Interestingly, in two recent trials from the UK assessing the efficacy of 4% dimeticone, cure rates of about 70% were reported, but in moderately infested individuals, cure rates were only 39%and64%4%, respectively [ 17, 18].
A recent trial from Bangladesh showed markedly more rapid atropinisation of OP-poisoned patients with a doubling dose regimen of atropine rather than a standard bolus dose regimen.
The role of antibiotics is debated and in the recent trial from Daniels et al. antibiotic treatment was not significantly more effective than placebo.
In addition, a recent trial from Frustraci et al. showed clearly that in patients with viral persistence undergoing immunosuppressive therapy, the mortality was significantly increased [ 20].
However, tumor cell contamination in PBSC is low, even when the cells are collected from a patient with residual tumor in the marrow, and a recent trial from the Children's Oncology Group failed to detect an impact of tumor cell purging of PBSC used for auto-HCT.
20 29 A recent trial from Bangladesh summarised that VIA should be used as the primary screening tool, although itss low sensitivity and specificity due to the limitations of a low-resource country, and the high false-positive results and overtreatment can be minimised by colposcopy evaluation of the VIA positive women.
I think we can say that control of hyperglycemia any kind of hyperglycemia, be it fasting or postprandial is still a difficult task, as learned from the recent trials, particularly from the Steno-2 (16), and also from the HEART2D.
Data obtained from a recent trial and from a systematic review were used in comparing the accuracy of MRI and VisionScope needle arthroscopy (VSI) with standard arthroscopy (gold standard).
The attenuating effects of acyclovir on HIV disease progression observed in recent trials may result both from direct anti-HIV activity as well as from indirect benefits of HSV-2 suppression.
This reiterates data from recent trials reporting increased fracture risk in women (but not men) and reports evidence from short term clinical trials in women that glitazones (both pioglitazone and rosiglitazone) caused more rapid bone loss.
However, it is clear from recent trials that study of this patient population presents challenges, and lessons must be learned from previous studies in which the selected trial population was too stable for any treatment effect to be detectable [ 17].
